Arrowhead Research | ARWR - Debt


Arrowhead Research reported $366.28M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Incyte USD 40.41M 855K Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Ligand Pharmaceuticals USD 451M 445.26M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Moderna USD 734M 7M Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 32.64B 1.37B Jun/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025
Xencor USD 69.27M 1.34M Sep/2025